Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

Diabetes mellitus (DM) is common in heart failure with preserved ejection fraction (HFpEF). Patients with DM and heart failure with reduced ejection fraction have higher levels of cardiac, profibrotic, and proinflammatory biomarkers relative to non‐diabetics. Limited data are available regarding the biomarker profiles of HFpEF patients with diabetes (DM) vs. no diabetes (non‐DM) and the impact of spironolactone on these biomarkers. This study aims to address such gaps in the literature.

[1]  Akshay S. Desai,et al.  Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction , 2018, Circulation. Heart failure.

[2]  G. Costa,et al.  Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes , 2018, Acta Diabetologica.

[3]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[4]  Vilmundur Gudnason,et al.  Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study , 2017, European heart journal.

[5]  P. Ponikowski,et al.  A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure , 2017, European journal of heart failure.

[6]  Akshay S. Desai,et al.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. , 2017, The New England journal of medicine.

[7]  Akshay S. Desai,et al.  Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. , 2017, JACC. Heart failure.

[8]  R. McKelvie,et al.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) , 2017, Circulation.

[9]  M. de Antonio,et al.  Impact of diabetes on the predictive value of heart failure biomarkers , 2016, Cardiovascular Diabetology.

[10]  Akshay S. Desai,et al.  Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[11]  S. Yusuf,et al.  Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia , 2015, Circulation.

[12]  Peter Van Buren,et al.  Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin , 2015, Circulation.

[13]  Spiros Denaxas,et al.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.

[14]  R. Wachter,et al.  Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.

[15]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[16]  Robert J Mentz,et al.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[17]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[18]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[19]  J. Cleland,et al.  Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial , 2012, European journal of heart failure.

[20]  Akshay S. Desai,et al.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.

[21]  James D. Thomas,et al.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. , 2011, The American journal of cardiology.

[22]  S. Donnelly,et al.  Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover , 2009, European journal of heart failure.

[23]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[24]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[25]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[26]  H. Eichler,et al.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. , 1995, The American journal of cardiology.

[27]  A. Grishman,et al.  New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.